Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know

Core Viewpoint - Zevra Therapeutics (ZVRA) has shown a significant price increase of 40.2% over the past four weeks, with a mean price target of $23.86 indicating an upside potential of 86.6% from the current price of $12.79 [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $3.39, where the lowest estimate is $19.00 (48.6% increase) and the highest is $29.00 (126.7% increase) [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding ZVRA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with potential stock price movements [11] - Over the last 30 days, two earnings estimates for ZVRA have increased, leading to a Zacks Consensus Estimate increase of 145.2% [12] Zacks Rank and Investment Potential - ZVRA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a useful guide for potential price movements [14]